312 related articles for article (PubMed ID: 32858235)
1. A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis.
Ikeda S; Kato T; Kenmotsu H; Ogura T; Iwasawa S; Sato Y; Harada T; Kubota K; Tokito T; Okamoto I; Furuya N; Yokoyama T; Hosokawa S; Iwasawa T; Yamanaka T; Okamoto H
J Thorac Oncol; 2020 Dec; 15(12):1935-1942. PubMed ID: 32858235
[TBL] [Abstract][Full Text] [Related]
2. Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study.
Ikeda S; Kato T; Kenmotsu H; Ogura T; Sato Y; Hino A; Harada T; Kubota K; Tokito T; Okamoto I; Furuya N; Yokoyama T; Hosokawa S; Iwasawa T; Kasajima R; Miyagi Y; Misumi T; Okamoto H
Oncologist; 2022 Sep; 27(9):720-e702. PubMed ID: 35759340
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study.
Ikeda S; Kato T; Kenmotsu H; Ogura T; Iwasawa S; Iwasawa T; Kasajima R; Miyagi Y; Misumi T; Yamanaka T; Okamoto H
Ther Adv Med Oncol; 2020; 12():1758835920922022. PubMed ID: 32426051
[TBL] [Abstract][Full Text] [Related]
4. A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
Fujimoto D; Morimoto T; Ito J; Sato Y; Ito M; Teraoka S; Otsuka K; Nagata K; Nakagawa A; Tomii K
Lung Cancer; 2017 Sep; 111():1-5. PubMed ID: 28838377
[TBL] [Abstract][Full Text] [Related]
5. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
Passiglia F; Galvano A; Rizzo S; Incorvaia L; Listì A; Bazan V; Russo A
Int J Cancer; 2018 Mar; 142(6):1277-1284. PubMed ID: 29080213
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
7. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K
Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
[TBL] [Abstract][Full Text] [Related]
9. Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey.
Hata H; Mio T; Yamashita D; Matsumura C; Chisaki Y; Motohashi H; Yano Y
Cancer Control; 2020; 27(4):1073274820977200. PubMed ID: 33297768
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
[No Abstract] [Full Text] [Related]
12. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.
Voong KR; Hazell SZ; Fu W; Hu C; Lin CT; Ding K; Suresh K; Hayman J; Hales RK; Alfaifi S; Marrone KA; Levy B; Hann CL; Ettinger DS; Feliciano JL; Peterson V; Kelly RJ; Brahmer JR; Forde PM; Naidoo J
Clin Lung Cancer; 2019 Jul; 20(4):e470-e479. PubMed ID: 31031204
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
Nishino M; Giobbie-Hurder A; Hatabu H; Ramaiya NH; Hodi FS
JAMA Oncol; 2016 Dec; 2(12):1607-1616. PubMed ID: 27540850
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer.
Ramagopalan S; Gupta A; Arora P; Thorlund K; Ray J; Subbiah V
JAMA Netw Open; 2021 Nov; 4(11):e2134299. PubMed ID: 34767024
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer.
Tamiya A; Tamiya M; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Inoue T; Okishio K; Nishino K; Kumagai T; Suzuki H; Hirashima T; Imamura F; Atagi S
Anticancer Res; 2017 Sep; 37(9):5199-5205. PubMed ID: 28870955
[TBL] [Abstract][Full Text] [Related]
17. EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.
Oshima Y; Tanimoto T; Yuji K; Tojo A
JAMA Oncol; 2018 Aug; 4(8):1112-1115. PubMed ID: 29327061
[TBL] [Abstract][Full Text] [Related]
18. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
Horn L; Gettinger SN; Gordon MS; Herbst RS; Gandhi L; Felip E; Sequist LV; Spigel DR; Antonia SJ; Balmanoukian A; Cassier PA; Liu B; Kowanetz M; O'Hear C; Fassò M; Grossman W; Sandler A; Soria JC
Eur J Cancer; 2018 Sep; 101():201-209. PubMed ID: 30077125
[TBL] [Abstract][Full Text] [Related]
19. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
20. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]